10172-35-7

Basic information

• Product Name: 2-BroMo-4-Methoxy-6-nitroaniline
• Synonyms: 2-BroMo-4-Methoxy-6-nitroaniline;4-AMino-3-broMo-5-nitroanisole[2-BroMo-4-Methoxy-6-nitroaniline];4-Amino-3-bromo-5-nitroanisole
• CAS NO: 10172-35-7
• Molecular Formula: C₇H₇BrN₂O₃
• Molecular Weight: 247.04608
• Mol File: 10172-35-7.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 352.1±37.0 °C(Predicted)
• Appearance: /
• Density: 1.718±0.06 g/cm3 (20 ºC 760 Torr)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: -1.24±0.25(Predicted)
• CAS DataBase Reference: 2-BroMo-4-Methoxy-6-nitroaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BroMo-4-Methoxy-6-nitroaniline(10172-35-7)
• EPA Substance Registry System: 2-BroMo-4-Methoxy-6-nitroaniline(10172-35-7)

Safety Data

• Hazardous Substances Data: 10172-35-7(Hazardous Substances Data)

Usage

General Description

2-Bromo-4-Methoxy-6-nitroaniline is a chemical compound with the molecular formula C7H6BrN3O3. It is a derivative of aniline and contains both bromine and nitro groups. 2-BroMo-4-Methoxy-6-nitroaniline is used in the synthesis of pharmaceuticals and agrochemicals, as well as in the production of dyes and pigments. It is also used as an intermediate in organic synthesis and in the manufacturing of other chemicals. 2-Bromo-4-Methoxy-6-nitroaniline is a yellow solid at room temperature and has potential environmental and health hazards, so proper handling and safety precautions are necessary when working with this chemical.

Upstream product

• 96-96-8 4-methoxy-2-nitroaniline 
• 119-81-3 4-methoxy-2-nitroacetanilide 

Downstream Products

• 10172-36-8 2,3-dibromo-5-methoxynitrobenzene 
• 98546-54-4 3-bromo-5-methoxybenzene-1,2-diamine 
• 201412-12-6 2-amino-5-methoxy-3-nitrobenzonitrile 

Relevant articles and documents

SUBSTITUTED QUINAZOLINE COMPOUNDS AND THEIR USE AS INHIBITORS OF G12C MUTANT KRAS, HRAS AND/OR NRAS PROTEINS

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I) or a pharmaceutically acceptable salt, stereoisomer or prodrug thereof, wherein R, R1, R2a, R2b, R2c, A, B, L1 and E are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of G12C mutant KRAS protein for treatment of disorders, such as cancer, are also provided.

Solid state nuclear bromination with N-bromosuccinimide. Part 1. Experimental and theoretical studies on some substituted aniline, phenol and nitro aromatic compounds

Solid state bromination of a number of substituted phenol, aniline and nitro aromatic compounds with N-bromosuccinimide yields exclusively the nuclear brominated products. Reactivity in the solid state depends on the reaction time, temperature and nature of the substituent on the substrate. The reaction apparently proceeds by an electrophilic aromatic substitution pathway. Molecular orbital and reaction free energy calculations also support such a view. Thermal analysis and video microscopic observation reveal the nature of the solid state reaction. Crystallinity is required for the reactivity and product selectivity. Product yield decreases with loss of selectivity when the reaction is carried out in a melt or in solution. Unlike the topochemical solid state reactions wherein molecular packing is more important than the intrinsic reactivity, these reactions demonstrate the importance of both these factors.